Top Stories

Meet the 5 diagnostics finalists for INVEST Pitch Perfect contest. Register now to get the Earlybird rate.

Our annual INVEST conference will be held as a virtual event this year. We will highlight the seismic changes in healthcare from July 20-24 and spotlight top startups and growth stage companies and how healthcare innovation is contending with the coronavirus public health crisis.

Check out the agenda here and register today. Earlybird Registration for MedCity Invest 2020 is available now for $ 49 if you register with the code MCN50. Full price tickets are $ 99. Companies can also opt to purchase 10 tickets for a corporate group rate of $ 399.

Meet the diagnostics startups who will take part in INVEST Pitch Perfect:

Amplified Sciences is a molecular diagnostics company using ultra-sensitive molecular sensing technology with composition of matter IP. The first application – early detection of pancreatic cancer – is an assay that will quickly prove the investment thesis due to large unmet medical need and a favorable reimbursement path.

CEO: Diana Caldwell

Headquarters: Indianapolis, IN

Atom Bioworks is a pioneer and leader in practice PEST (Pattern-matching Enabled Sensing & Theraputics) medicine by creating nanoscale biosensing and theraputics platform powered by innovative DNA nanostructures.

CEO: Sherwood Yao

Headquarters: Cary, NC

Exogene Bio is a diagnostics and medical device company whose goal is to enter the liquid biopsy market in order to simultaneously isolate exosomes and cell-free biomarkers using proprietary nanofluidic technology. This technology will then be integrated into an automated medical diagnostic device for the simultaneous detection of multiple classes of cancers using early stage biomarkers contained within exosomes and in cell-free fractions of body fluids.

CEO: Anant Kamath

Headquarters: Iowa City, IA

Inanovate has developed a patented blood analysis system (the Bio-ID) that improves the cost, accessibility, and accuracy of diagnostic tests. The first application of the Bio-ID is a new blood test to be used as a supplement to mammography to help reduce false positive results in breast cancer screening.

CEO: David Ure

Headquarters: Research Triangle Park, NC

Total Blood Profile is commercializing a revolutionary diagnostic platform developed by the Monash University Centre for Biospectroscopy. Its patented tests have achieved proof of concept for the rapid quantitative detection of pathogens and biomarkers in bodily fluids at point-of-care.

Directors: Bayden R. Wood, Philip Heraud, Peter Harper

Headquarters: Melbourne, Australia

Check out participants in the Pitch Perfect competition here.

Each day of the week will feature a pitch competition highlighting five startups in these tracks – Health Services, Health IT, Medical Devices, Biopharma and Diagnostics. Presenters will highlight their vision for changing healthcare followed up by a Q&A with investor judges. Winners for each track will be announced on July 27 on our website.

All the sessions will be recorded and be available to attendees upon request.

MedCity Invest will be a full week deep-dive into Healthcare Investing. Register now with the code MCN50 for the early bird rate of $ 49 to access the 5 pitch competitions, keynotes, panels, virtual networking and more!

Photo: Rawpixel, Getty Images

Let’s block ads! (Why?)

MedCity News

Leave a Reply

Your email address will not be published. Required fields are marked *